Inventiva SACA

Inventiva to host a webcast with Key Opinion Leaders following the EASL International Liver Congress™ 2022

16 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces three scientific presentations at the EASL International Liver Congress™ 2022

09 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva joins the Euronext Tech Leaders segment

07 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

 Inventiva announces the presentation of a scientific abstract at the 82nd Scientific Sessions of the American Diabetes Association

03 Jun 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces participation at several investors conferences in May and June 2022

23 May 2022 15:00:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ Meeting of May 19, 2022

20 May 2022 15:00:00 By Nasdaq GlobeNewswire

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 19 May 2022

19 May 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

16 May 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva secures a €50 million credit facility from the European Investment Bank

16 May 2022 01:00:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022

28 Apr 2022 09:35:00 By Nasdaq GlobeNewswire

Combined General Meeting of May 19, 2022 - Availability of the preparatory documents

28 Apr 2022 09:30:00 By Nasdaq GlobeNewswire

 Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver

07 Apr 2022 15:00:00 By Nasdaq GlobeNewswire

 Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F

11 Mar 2022 15:44:49 By Nasdaq GlobeNewswire

 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

08 Mar 2022 01:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2021 Full-Year Results: key milestones achieved with lanifibranor in NASH and cedirogant in psoriasis

07 Mar 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces participation at several conferences in March 2022

01 Mar 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2021 Full-Year Financial Results

28 Feb 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports cash position and revenues for Full-Year 2021

14 Feb 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva receives a €4 million milestone payment from AbbVie for cedirogant Phase IIb initiation

31 Jan 2022 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces participation at several conferences in January and February 2022

20 Jan 2022 15:00:00 By Nasdaq GlobeNewswire